David N. Chernoff

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Schiff Nutrition International, Inc. operates as a nutritional supplement company which offers vitamins, nutrition supplements and nutrition bars in the U. S. and abroad. Its portfolio consists of brands, including, MegaRed, Move Free, Airborne, Tiger's Milk, Sustenex, Digestive Advantage and Schiff vitamins. The company also manufactures and distributes private label products which include specialty supplements, vitamins and minerals, such as joint care products, Vitamin B and Calcium Citrate. Schiff Nutrition International was founded in 1940 and is headquartered in Salt Lake City, UT.

Part of Bayer AG, Chiron Diagnostics Corp. is a private company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million.

Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.